Intravail: highly effective intranasal delivery of peptide and protein drugs.
Recent development of a new class of patented alkylsaccharide transmucosal delivery enhancement agents, collectively designated as Intravail (Aegis Therapeutics) absorption enhancers, has created opportunities for new therapeutic options across a broad spectrum of human diseases. Intravail absorption enhancers provide unsurpassed intranasal bioavailabilities, comparable to those that are achieved by injection for protein, peptide and other macromolecular therapeutics. These novel, highly effective and non-irritating excipients circumvent the two primary limitations of intranasal drug delivery, namely mucosal irritation and poor bioavailability, and offer the promise of more convenient, more effective and safer therapeutics for patients and physicians alike. For pharmaceutical companies, Intravail provides a means to capitalise on two important industry dynamics: rapidly growing industry interest in commercialising peptide and protein drugs, and increasing interest in, and use of, the intranasal route for systemic drug delivery.
Maggio
Edward T
ET
Aegis Therapeutics LLC, 16870 West Bernardo Drive, Suite 390, San Diego, CA 92127, USA. emaggio@aegisthera.com
D000281:Administration, Intranasal; D000327:Adsorption / Q000187:drug effects; D000818:Animals; D001682:Biological Availability; D003837:Deoxy Sugars / Q000009:adverse effects / Q000494:pharmacology; D004337:Drug Carriers / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D036501:Metered Dose Inhalers; D009297:Nasal Mucosa / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D011506:Proteins / Q000008:administration & dosage* / Q000493:pharmacokinetics
D003837:Deoxy Sugars; D004337:Drug Carriers; D010455:Peptides; D004364:Pharmaceutical Preparations; D011506:Proteins